All relevant data are within the paper.

Introduction {#sec001}
============

Human enteric viruses constitute a serious public health concern, since they are capable of causing a variety of acute illnesses, including the most commonly reported acute gastrointestinal illness. They are mainly transmitted *via* the fecal-oral route either by person-to-person contact or by ingestion of contaminated water and food, particularly shellfish, soft fruits and vegetables. Enteric viruses are shed in enormous quantities in feces (10^9^ to 10^10^/g) and have an infectious dose on the order of tens to hundreds of virions. Enteric viruses are host-specific and are not capable of replicating in the environment, but they survive for long periods of time on food or food contact surfaces or in water (ground, surface, and drinking water) \[[@pone.0147832.ref001]\]. These characteristics enable enteric viruses to play a significant role in food- and waterborne outbreaks. Aside from noroviruses, which have been recognized as the largest cause of outbreaks, the viruses most often implicated in outbreaks include hepatitis viruses (hepatitis A virus and hepatitis E virus), rotavirus, adenovirus (40, 41), astrovirus, enterovirus \[[@pone.0147832.ref002], [@pone.0147832.ref003], [@pone.0147832.ref004], [@pone.0147832.ref005], [@pone.0147832.ref006], [@pone.0147832.ref007]\]. Additional viruses of lesser epidemiologic importance include human bocavirus, cosavirus, parvovirus, sapovirus, tick-borne encephalitis virus (TBEV), Aichi virus, and coronavirus \[[@pone.0147832.ref008], [@pone.0147832.ref009], [@pone.0147832.ref010], [@pone.0147832.ref011]\].

Tools for rapid detection of viral pathogens are important for analyzing clinical, environmental and food samples. Detection of these enteric viruses based on their infectivity is complicated by the absence of a reliable cell culture method and the low levels of contamination of food and environmental samples \[[@pone.0147832.ref012],[@pone.0147832.ref013]\]. To date, real time RT-PCR has been one of the most promising detection methods due to its sensitivity, specificity, and speed. Recently, the ISO/TS 15216--1 and 15216--2 standards covering real time RT-PCR for both quantitative determination and qualitative detection of NoV and HAV in foodstuffs were published \[[@pone.0147832.ref014], [@pone.0147832.ref015], [@pone.0147832.ref016]\].

The aim of this study was to develop real time RT-PCR assays for detection of a total of 19 human enteric viruses (including 3 genogroupes of norovirus and 4 coronaviruses) and two control process viruses (mengovirus and murine norovirus) generally used for monitoring the recovery of viral foodstuff extraction methods. Limits of detection of the viral genomes were determined with the conventional RT-qPCR system and with the Fluidigm's BioMark System by using the qualitative nanofluidic real-time RT-PCR array and the quantitative digital RT-PCR array. The advantages of these new detection techniques were determined by detecting and quantifying pathogenic viruses in clinical samples.

Methods {#sec002}
=======

Viruses and cells {#sec003}
-----------------

HAV strain HM175/18f, clone B (VR-1402), was obtained from the American Type Culture Collection (ATCC). This clone replicates rapidly and has cytopathic effects in cell culture \[[@pone.0147832.ref017]\]. HAV stock was produced by propagation in foetal rhesus monkey kidney (FRhK-4) cells (ATCC, CRL-1688) \[[@pone.0147832.ref018]\] and titrated by plaque assay \[[@pone.0147832.ref019]\]. The titer of viral production was established in HAV RNA genomic copies with an RT-qPCR standard curve obtained with the ten-fold diluted *in vitro* RNA transcripts. Based on this approach, HAV stocks had titres of 9.33 x 10^8^ genome copies / mL.

Dr. H. Virgin from Washington University in the USA provided ANSES's Fougères Laboratory in France with MNV-1 (CW1 strain) which was then propagated in mouse leukemic monocyte macrophage (RAW 264.7, ATCC TIB-71) cell line \[[@pone.0147832.ref020]\]. MNV-1 stock was produced as previously described \[[@pone.0147832.ref021]\]. The extracted RNA was confirmed with RT-qPCR and quantified by measuring absorbance at 260 / 280 nm with a NanoDrop ND-1000. Based on this approach, the production stock of MNV-1 had titres of approximately 1.36 x 10^12^ genome copies / mL.

Mengovirus (strain MC~0~) was obtained from clarified supernatant provided by Dr. Albert Bosch from the "Enteric Virus Group" of the University of Barcelona. Mengovirus stock was produced by propagation in HeLa cells (ATCC, CCL-2^™^) \[[@pone.0147832.ref022]\]. The extracted RNA was confirmed with RT-qPCR and quantified by measuring absorbance at 260 / 280 nm with a NanoDrop ND-1000. Based on this approach, the production stock of MNV-1 had titres of approximately 6.68 x 10^11^ genome copies / mL.

Rotavirus strain Wa (human rotavirus) was obtained from the Pasteur Institute (Paris, France) and was propagated in MA-104 rhesus monkey epithelial cell line (ATCC CRL-2378) \[[@pone.0147832.ref023]\]. The extracted RNA was confirmed with RT-qPCR and quantified by measuring absorbance at 260 / 280 nm with a NanoDrop ND-1000. Based on this approach, the production stock of Wa had titres of approximately 3.21 x 10^11^ genome copies / mL.

Four viral strains were obtained from infected cell culture supernatants: two enterovirus strains (human B6 coxsackievirus (Schmitt strain: ATCC^®^ VR-1037AS/MK^™^) and human echovirus 19 (Burke strain)), one Adenovirus 40 strain (ATCC VR-931) and one Astrovirus GI strain.

Viruses and stools {#sec004}
------------------

The study was conducted in accordance with the ethics principles of the Declaration of Helsinki. Hepatitis A virus infection is a notifiable disease in France. The current system of mandatory reporting was approved by the Commission Nationale de l'Informatique et des Libertés (deliberation n° 02--082, November 19 2002). Patients receive oral and written information on the finality of the notification and on the modalities of information recording. This information is available on line on the web site of the Institut de Veille Sanitaire (IVS) at <http://www.invs.sante.fr/content/download/6498/42945/version/2/file/fiche_info_patient.pdf> for HAV samples and on the web site of the NRC at [www.cnr-ve.org](http://www.cnr-ve.org) for enteric virus samples. All clinical and biological parameters are treated anonymously. The virological surveillance of strain diversity is performed on stored samples obtained for hepatitis A diagnosis (no need for any additional blood draw). Diagnostic laboratories are asked to contribute to HAV and enteric virus strains surveillance by sending samples to the National Reference Centre (NRC). The study was not specifically approved by an ethics committee. Human samples were collected before the study and they are anonymously collected and analyzed.

The following human stool samples were provided by the National Reference Center (NRC) for Enteric Viruses (Dijon, France): adenovirus 41 (stool n°E5669), astrovirus GI (E4883), norovirus GI (E5486; E5569; E8050), norovirus GII (E6929; E6618; E7859; E7022; E6992), rotavirus (RV G12P8 = E7622; RV G1P8 = E8097), Aichi virus (E6841) and norovirus GII.13 + norovirus GIV.

The following human stool samples were provided by the National Reference Center (NRC) for HAV/HEV (Villejuif, France): HAV GIA (stools no. 780627147; 1181216151), HAV GIB (1280210015; 1280514230), HEV G3c (1280511146), HEV G3f (1280418084; 1280530128) and HEV G4 (1280615097; 1280522166).

The faecal samples were suspended in 1X Phosphate Buffered Saline (PBS), pH 7, to obtain a final 10% suspension (w/v), vortexed and centrifuged at 3000 g for 30 min at 4°C. Aliquots of 100 μL supernatant were kept frozen at -80°C for later use.

The extracted genomic RNA/DNA of adenovirus, astrovirus and rotavirus were confirmed with RT-qPCR and quantified by measuring absorbance at 260 / 280 nm with a NanoDrop ND-1000.

The extracted genomic RNA of norovirus GI, GII and GIV, sapovirus, Aichi virus, HAV and HEV were confirmed and quantified with RT-qPCR by using *in vitro* RNA standard curves (see "DNA and RNA standards").

DNA and RNA standards {#sec005}
---------------------

Sequences from reference strains were inserted into recombinant plasmids ([Table 1](#pone.0147832.t001){ref-type="table"}). The HEV, HAV, NoV GI and NoV GII cDNA were cloned in pGEM-T Easy vector (Promega, Charbonnières-les-Bains, France) and propagated in *E*. *coli* One Shot^®^ TOP10F' (Life technologies, Saint Aubin, France). High-quality DNA plasmids containing HAV or NoV regions were purified using the Qiagen Plasmid midi kit (Qiagen, Courtaboeuf, France) according to the manufacturer's protocol. Then, NoV GI plasmid was digested with NCOI (Life technologies), and HEV DNA, HAV DNA and NoV GII DNA plasmids were digested with SpeI (Life technologies) and transcripts were obtained by using a MEGAscript^®^ kit (Life technologies) according to the manufacturer's protocol. Synthesized RNA were treated with Turbo^™^ DNase (Life technologies) according to the manufacturer's protocol in order to remove the DNA template following transcription, and purified by using the MEGAclear^™^ kit (Life technologies). The synthesized DNA and RNA were confirmed with (RT)-qPCR and quantified by measuring absorbance at 260 / 280 nm with a NanoDrop ND-1000 (Thermoscientific, Courtaboeuf, France) and the free software available on the "<http://endmemo.com/bio/dnacopynum.php>" website. Aliquots of 10μL containing 10^9^ genome copies / μL were kept frozen at -20°C for later use and used as standards.

10.1371/journal.pone.0147832.t001

###### GenBank accession number for viral sequences used to obtain recombinant plasmids.

![](pone.0147832.t001){#pone.0147832.t001g}

  Virus               Reference sequence   Position of the genomic sequence cloned   Plasmid used
  ------------------- -------------------- ----------------------------------------- --------------------
  Hepatitis A virus   M59808.1             39--518                                   pGEM-T Easy vector
  Hepatitis E virus   AB097812             5301--5371                                pGEM-T Easy vector
  Norovirus GI        M87661               5257--5413                                pGEM-T Easy vector
  Norovirus GII       X86557               4981--5135                                pGEM-T Easy vector
  Norovirus GIV       JQ613567             4961--5140                                pBluescriptIISK
  Sapovirus           NC_006269            5051--5200                                pBluescriptIISK
  Aichi virus         AB040749             241--350                                  pBluescriptIISK
  TBEV                U27495               11031--11141                              pBluescriptIISK
  Parvovirus B19      AB550331             2221--2420                                pBluescriptIISK
  Cosavirus           NC_012800            701--860                                  pBluescriptIISK
  Bocavirus           NC_012042            2511--2700                                pBluescriptIISK
  229E                AF304460             25351--25530                              pBluescriptIISK
  HKU1                HM034837.1           28751--28940                              pBluescriptIISK
  NL63                JX504050             26191--26380                              pBluescriptIISK
  OC43                JN129835.1           28791--28940                              pBluescriptIISK

Sapovirus, TBEV, norovirus GIV, Aichi virus, 229E, HKU1, cosavirus, OC43 and NL63 cDNA were cloned into the pBluescriptIISK+ vector by Genecust (Dudelange, Luxembourg). All recombinant plasmids were purified by Genecust and used to produce RNA transcripts. Sapovirus, TBEV, norovirus GIV, 229E, cosavirus and NL63 DNA plasmids (0.5 μg) were digested with *EcoR*V (Life technologies) and Aichi virus, HKU1 and OC43 DNA plasmids were digested with *Spe*I (Life technologies).

Digested plasmids were transcribed by using the MEGAscript^®^ kit (Life technologies) according to the manufacturer's protocol. Synthesized RNA was treated with Turbo^™^ DNase (Life technologies) according to the manufacturer's protocol in order to remove the DNA template following transcription, and purified by using the MEGAclear kit (Life technologies) according to manufacturer's instructions. The synthesized RNA was confirmed with RT-qPCR and quantified by measuring absorbance at 260 / 280 nm with a Nanodrop ND-100 (Thermoscientific, France) and the free software available on the "<http://endmemo.com/bio/dnacopynum.php>" website. RNA stocks were diluted to contain 10^9^ copies / μL. Aliquots of 10 μL were kept frozen at -20°C for later use as standards.

Bocavirus and parvovirus cDNA were cloned into the pBluescriptIISK+ vector by Genecust (Dudelange, Luxembourg). Both recombinant plasmids were purified by Genecust. DNA plasmids (0.5 μg) were digested with *Spe*I (Life technologies) to be linearized. The synthesized DNA was confirmed with qPCR and quantified by measuring absorbance at 260 / 280 nm with a Nanodrop ND-100 (Thermoscientific, France) and the free software available on the "<http://endmemo.com/bio/dnacopynum.php>" website. DNA stocks were diluted to contain 10^9^ copies / μL. Aliquots of 10 μL were kept frozen at -20°C for later use as standards.

Nucleic acid extraction {#sec006}
-----------------------

Adenovirus 40, adenovirus 41, astrovirus, rotavirus, coxsackievirus B6, MNV-1, mengovirus, HAV (HM175/18f, HAV GIA and HAV GIB), HEV (HEV G3c, HEV G3G et HEV G4), NoV (GI, GII, GII+GIV), sapovirus, echovirus 19, Aichi virus, and astrovirus DNA or RNA were extracted using the NucliSens^®^ easyMAG^™^ platform (Biomérieux Marcy l'Etoile, France) for total nucleic acid extraction by the 'off board Specific A" protocol according to manufacturer's instructions. Nucleic acids were eluted in 100 μL of elution buffer and stored at -80°C.

Adenovirus 41, astrovirus, rotavirus, coxsackievirus B6, MNV-1 and mengovirus DNA or RNA were confirmed with (RT)-qPCR and quantified by measuring absorbance at 260 / 280 nm with a NanoDrop ND-1000 (Thermoscientific, Courtaboeuf, France) and used as standards.

Extracted RNA from HAV (HM175/18f, HAV GIA and HAV GIB), HEV (HEV G3c, HEV G3G and HEV G4), NoV (GI, GII, GII+GIV), sapovirus, echovirus 19, Aichi virus, adenovirus 40 and astrovirus were quantified with (RT)-qPCR using standards (*in vitro* transcripted RNA, plasmidic DNA, extracted genomic RNA).

Primers and probes {#sec007}
------------------

The primers and probes used to detect all the viruses of this study are described in [Table 2](#pone.0147832.t002){ref-type="table"}. Those used to detect NoV GI, NoV GII, HAV and mengovirus are described in ISO/ TS 15216--1 / 15216--2 (2013). All the primers and probes were purchased from Life Technologies or Eurofins MWG Operon (Les Ulis, France).

10.1371/journal.pone.0147832.t002

###### Primers and probes used in this study.

(F: Forward; R: Reverse; P: Probe)

![](pone.0147832.t002){#pone.0147832.t002g}

  Virus                          Specificity                         Sequence (5'---3')                                     Location Size   Target                         Reference
  ------------------------------ ----------------------------------- ------------------------------------------------------ --------------- ------------------------------ -------------------------------------
  Hepatitis A virus              All genotypes                       `F—TCA CCG CCG TTT GCC TAG`                            68--85          5'UTR                          \[[@pone.0147832.ref022]\]
                                                                     `R—GGA GAG CCC TGG AAG AAA G`                          241--223        M14707                         \[[@pone.0147832.ref022]\]
                                                                     `P—FAM-CCT GAA CCT GCA GGA ATT AA-MGB`                 169--150        174bp                          \[[@pone.0147832.ref022]\]
  Hepatitis E virus              All genotypes                       `F—CGG TGG TTT CTG GGG TGA C`                          5260--5278      ORF2/ORF3                      \[[@pone.0147832.ref035]\]
                                                                     `R—AGG GGT TGG TTG GAT GAA TAT AG`                     5330--5308      M73218                         \[[@pone.0147832.ref035]\]
                                                                     `P—FAM-GGG TTG ATT CTC AGC CCT TCG C-BHQ1`             5280--5301      71bp                           \[[@pone.0147832.ref035]\]
  Rotavirus                      Serotype A                          `F—ACC ATC TWC ACR TRA CCC TC`                         963--982        NSP3 (segment 7)               \[[@pone.0147832.ref036]\], adapted
                                                                     `R—GGT CAC ATA ACG CCC C`                              1049--1034      X81436                         \[[@pone.0147832.ref037]\]
                                                                     `P—FAM-ACA ATA GTT AAA AGC TAA CAC TGT CAA-BHQ1`       990--1016       87pb                           \[[@pone.0147832.ref036]\], adapted
  Norovirus                      Genogroup I                         `F—CGC TGG ATG CGN TTC CAT`                            5291--5308      5\' end of ORF2                \[[@pone.0147832.ref038]\]
                                                                     `R—CCT TAG ACG CCA TCA TCA TTT AC`                     5376--5334      M87661                         \[[@pone.0147832.ref039]\]
                                                                     `P—FAM-TGG ACA GGA GAY CGC RAT CT-BHQ1`                5321--5340      86bp                           \[[@pone.0147832.ref039]\]
  Norovirus                      Genogroup II                        `F—ATG TTC AGR TGG ATG AGR TTC TCW GA`                 5012--5037      5\' end of ORF2                \[[@pone.0147832.ref040]\]
                                                                     `R—TCG ACG CCA TCT TCA TTC ACA`                        5080--5100      X86557                         \[[@pone.0147832.ref041]\]
                                                                     `P—FAM-AGC ACG TGG GAG GGC GAT CG-BHQ1`                5042--5061      89bp                           \[[@pone.0147832.ref040]\]
  Norovirus                      Genogroup IV                        `F—GGA TGC GRT TCT CAG ACT`                            4986--5003      ORF1-ORF2                      This study
                                                                     `R—TCT TCA TTC ACA AAR TCG GGA G`                      5055--5034      JQ613567                       This study
                                                                     `P—FAM-TGG GAG GGG GAT CGC GAT CT-BHQ1`                5012--5031      70bp                           \[[@pone.0147832.ref042]\]
  Sapovirus                      GG 1, 2, 4, 5                       `F—GAC CAG GCT CTC GCY ACC TAC`                        5074--5094      Polymerase / capsid junction   \[[@pone.0147832.ref043]\]
                                                                     `R—CCC TCC ATY TCA AAC ACT AWT TTG`                    5177--5154      NC_006269                      \[[@pone.0147832.ref043]\]
                                                                     `P—FAM-CCC ACT GGG TCA RGT ACT GTA C-BHQ1`             5135--5114      104bp                          This study
  Aichi virus                    /                                   `F—CCA GCC TGA CGT ATC ACA GG`                         268--287        5' UTR                         \[[@pone.0147832.ref044]\]
                                                                     `R—CAC AAT TGC CAC GTG AGC AGC TT`                     329--307        AB040749                       \[[@pone.0147832.ref044]\]
                                                                     `P—FAM-CTG TGT GAA GYC C-MGB`                          288--300        62bp                           \[[@pone.0147832.ref044]\]
  Astrovirus                     /                                   `F—TCT YAT AGA CCG YAT TAT TGG`                        2209--2229      ORF 1a                         \[[@pone.0147832.ref045]\]
                                                                     `R—TCA AAT TCT ACA TCA TCA CCA A`                      2322--2301      NC_001943                      \[[@pone.0147832.ref045]\]
                                                                     `P—FAM-CCC CAD CCA TCA TCA TCT TCA TCA-BHQ1`           2295--2272      114bp                          \[[@pone.0147832.ref045]\]
  Adenovirus                     40 and 41 (serotype F)              `F—CTC GAC ATG ACT TTT GAG GT`                         20256--20275    Hexon protein                  \[[@pone.0147832.ref045]\], adapted
                                                                     `R—GTA GAC GGC CTC GAT GAC`                            20375--20358    NC_001454                      \[[@pone.0147832.ref045]\], adapted
                                                                     `P—FAM-AGG ATG AGC CCA CAC TTC TYA TGB-BHQ1`           20290--20302    120bp                          \[[@pone.0147832.ref045]\], adapted
  Coronavirus (human)            229 (α-coronaV)                     `F—CAT ACT ATC AAC CCA TTC AAC AAG`                    25374--25397    glycoprotein                   \[[@pone.0147832.ref046]\]
                                                                     `R—CAC GGC AAC TGT CAT GTA TT`                         25510--25491    AF304460                       \[[@pone.0147832.ref046]\]
                                                                     `P—FAM-ATG AAC CTG AAC ACC TGA AGC CAA TCT ATG-BHQ1`   25480--25451    137bp                          \[[@pone.0147832.ref047]\]
                                 HKU1 (β-coronaV)                    `F—TCC TAC TAY TCA AGA AGC TAT CC`                     28775--28797    phosphoprotein                 \[[@pone.0147832.ref046]\]
                                                                     `R—AAT GAA CGA TTA TTG GGT CCA C`                      28921--28900    HM034837.1                     \[[@pone.0147832.ref046]\]
                                                                     `P—FAM-TYC GCC TGG TAC GAT TTT GCC TCA-BHQ1`           28808--28831    147bp                          \[[@pone.0147832.ref047]\]
                                 NL63 (α-coronaV)                    `F—GTT CTG ATA AGG CAC CAT ATA GG`                     26215--26237    phosphoprotein                 \[[@pone.0147832.ref046]\]
                                                                     `R—TTT AGG AGG CAA ATC AAC ACG`                        26357--26337    JX504050                       \[[@pone.0147832.ref046]\]
                                                                     `P—FAM-CGC ATA CGC CAA CGC TCT TGA ACA-BHQ1`           26326--26303    143bp                          \[[@pone.0147832.ref047]\]
                                 OC43 (β-coronaV)                    `F—CAT ACY CTG ACG GTC ACA ATA ATA`                    28812--28835    glycoprotein                   \[[@pone.0147832.ref046]\]
                                                                     `R—ACC TTA GCA ACA GTC ATA TAA GC`                     28921--28899    JN129835.1                     \[[@pone.0147832.ref046]\]
                                                                     `P—FAM-TGC CAA AGA ATA GCC ART ACC TAG T-BHQ1`         28889--28865    110bp                          \[[@pone.0147832.ref047]\], adapted
  Tick-born-encephalitis virus   European and Far-Eastern subtypes   `F—GGG CGG TTC TTG TTC TCC`                            11054--11071    3'NCR                          \[[@pone.0147832.ref048]\], adapted
                                                                     `R—ACW CAT CAC CTC CTT GTC AGA CT`                     11121--11099    U27495                         \[[@pone.0147832.ref048]\], adapted
                                                                     `P—FAM-TGA GCC ACC ATC ACC CAG ACA CA-BHQ1`            11073--11095    68bp                           \[[@pone.0147832.ref048]\], adapted
  Parvovirus                     B19                                 `F—CCC CGG GAC CAG TTC AGG`                            2241--2258      NS                             \[[@pone.0147832.ref049]\]
                                                                     `R—CCC CTY ACA CCR TCC CAC AC`                         2393--2374      AB550331                       \[[@pone.0147832.ref049]\]
                                                                     `P—FAM-ATC ATY TGT CGG AAG CYC AGT TTC CTC CG-BHQ1`    2262--2290      153bp                          \[[@pone.0147832.ref049]\]
  Enterovirus                    /                                   `F—GCC CCT GAA TGC GGC`                                334--348        Polyprotein                    \[[@pone.0147832.ref050]\]
                                                                     `R—GAT TGT CAC CAT AAG CAG C`                          481--464        AJ295199                       \[[@pone.0147832.ref051]\], adapted
                                                                     `P—FAM-CGG AAC CGA CTA CTT TGG GTG TCC GT-BHQ1`        416--441        148pb                          \[[@pone.0147832.ref051]\]
  Cosavirus                      /                                   `F—TTG TAG YGA TGC TGT RTG TGT GTG`                    735--758        5'-UTR                         \[[@pone.0147832.ref052]\], adapted
                                                                     `R—CCA YTG TGT GGG TCC TTT CG`                         827--808        NC_012800                      \[[@pone.0147832.ref052]\], adapted
                                                                     `P—FAM-CYC ACA GGC CRR AAG CCC TGT C-BHQ1`             783--807        93bp                           \[[@pone.0147832.ref052]\], adapted
  Bocavirus                      hBoV2                               `F—TCA GAC CAA GCG ACG AAG AC`                         2531--2550      Gene *NP-1*                    \[[@pone.0147832.ref053]\]
                                                                     `R—CTC TAG CAA GYC TAG TAG AAT GCC`                    2675--2652      NC_012042                      \[[@pone.0147832.ref053]\]
                                                                     `P—FAM-AAC CCA CAC CAT CCA GGA GCA TCT G-BHQ1`         2646--2622      145bp                          \[[@pone.0147832.ref053]\]
  MNV                            MNV-1                               `F—CCG CCA TGG TCC TGG AGA ATG-3'`                     3193--3213      Polyprotein                    \[[@pone.0147832.ref054]\]
                                                                     `R—GCA CAA CGG CAC TAC CAA TCT TG-3'`                  3330--3308      DQ285629                       \[[@pone.0147832.ref054]\]
                                                                     `P—FAM-CGT CGT CGC CTC GGT CCT TGT CAA-BHQ1`           3227--3250      138bp                          \[[@pone.0147832.ref054]\]
  Mengovirus                     MC~0~                               `F—GCG GGT CCT GCC GAA AGT`                                            5'NTR                          \[[@pone.0147832.ref055]\]
                                                                     `R—GAA GTA ACA TAT AGA CAG ACG CAC AC`                 /                                              \[[@pone.0147832.ref055]\]
                                                                     `P—FAM-ATC ACA TTA CTG GCC GAA GC-MGB`                                 100bp                          \[[@pone.0147832.ref055]\]

RT-qPCR with the CFX96^™^ real time PCR detection system {#sec008}
--------------------------------------------------------

One-step RT-qPCR amplifications were performed on a CFX96^™^ real time PCR detection system from Bio-Rad (Marnes-la-Coquette, France). Reactions were performed in a 15 μL reaction mixture containing 1X of RNA UltraSense^™^ master mix and 0.63 μL of RNA Ultrasense^™^ enzyme mix, which are components of the RNA UltraSense^™^ One-Step Quantitative RT-PCR System (Life technologies), 2 U RNAse inhibitor (Life technologies), 5 μg of bovine serum albumin (Life Technologies), 500 nM of forward primer, 900 nM of reverse primer, 250 nM of probe, and 5 μL of RNA extract. A negative control containing all the reagents except the RNA template was included with each set of reaction mixtures.

The one-step RT-qPCR program involved 60 min reverse transcription of RNA at 55°C, followed by a 15 min denaturation step at 95°C, 45 cycles of 15 s at 95°C, 1 min at 60°C and 1 min at 65°C. Fluorescence was recorded by the apparatus at the end of the elongation steps (1 minute at 65°C) for each amplification cycle. All samples were characterised by a corresponding Ct value. Negative samples gave no Ct value. A standard curve for each target was generated with synthesized RNA (HAV, HEV, NoV GI, NoV GII, NoV GIV, sapovirus, cosavirus, Aichi virus, human coronavirus (HKU1, 229E, NL63, OC43), TBEV), RNA extracts (rotavirus, astrovirus, enterovirus, MNV and mengovirus), synthesized DNA (parvovirus, bocavirus) or DNA extract (adenovirus) resulting from serial dilution in ultrapure water. The slopes (*S*) of the regression lines were used to calculate the amplification efficiency (*E*) of the RT-qPCR reactions, according to the formula *E* = 10^\|-1/s\|^-1, to determine the RT-qPCR assay performance.

RT-dPCR with the BioMark System {#sec009}
-------------------------------

Digital PCR works by partitioning a single sample into hundreds of individual PCR reactions. RT-dPCR amplifications were performed on a Fluidigm BioMark System by using qdPCR 37k IFC digital array microfluidic chips (Les Ulis, France). Utilizing nanoscale valves and channels, the Biomark Integrated Fluidic Circuit (IFC) controller partitions each of the 48 samples premixed with PCR reagents into a panel of 770 PCR reaction chambers (i.e. 36,960 individual qPCR reactions on a digital array). By counting the number of positive reactions, the number of target molecules in each sample can be accurately estimated based on the Poisson distribution.

Reactions were performed in a 10 μL reaction mixture containing 1X of RNA UltraSense^™^ master mix, 1X of ROX reference dye and 0.44 μL of RNA Ultrasense^™^ enzyme mix, which are components of the RNA UltraSense^™^ One-Step Quantitative RT-PCR System (Life Technologies), 1X of 20X GE Sample Loading Reagent (Fluidigm), 2 U RNAse inhibitor (Life Technologies), 500 nM of forward primer, 900 nM of reverse primer, 250 nM of probe, and 5.8 μL of RNA extract. A negative control containing all the reagents except the RNA template was included with each set of reaction mixtures. 6 μL out of ten reaction mix was charged onto the chip with the IFC controller MX, but 0.65 μL were effectively partitioned into the 770 chambers of one panel, including 0.38 μL of RNA extract.

The one-step RT-dPCR program involved 60 min reverse transcription of RNA at 55°C, followed by a 15 min denaturation step at 95°C, and lastly 45 cycles of 15 s at 95°C, 1 min at 60°C and 1 min at 65°C. Fluorescence was recorded by the apparatus at the end of the elongation steps (1 minute at 65°C) for each amplification cycle.

The Digital PCR Analysis software (Fluidigm) was used to count the number of positive chambers out of the total number of chambers per panel.

The Poisson distribution was used to estimate the average number of template copies per chamber in a panel \[[@pone.0147832.ref024], [@pone.0147832.ref025]\]. All samples were characterised by a corresponding absolute quantity. No positive chambers were observed in negative samples.

RT-qPCR with the BioMark System {#sec010}
-------------------------------

The 48.48 dynamic arrays were automatically loaded using an integrated fluidic circuit (IFC) controller (Fluidigm Corporation), and real-time reactions were performed and analyzed using a BioMark real-time PCR system and analysis software (Fluidigm Corporation), respectively. As a quality control, negative control samples were included on every array for each viral genome.

RT reactions were performed in a 25 μL reaction mixture containing 1X of First-Strand Buffer, 10mM of DTT and 1 μL of SuperScript^®^ III RT enzyme, which are components of SuperScript^®^ III Reverse Transcriptase (Life technologies), 2 U RNAse inhibitor (Life technologies), 2μM of Random hexamer (Life technologies), 200 μM of dNTP (Life technologies), and 10 μL of nucleic acids. A negative control containing all the reagents except the RNA template was included with each set of reaction mixtures. The RT program involved 5 min at 25°C, followed by 60 min at 55°C, and lastly 15 min at 70°C. Aliquots were kept frozen at -80°C for later use.

Preamplification reactions were performed in a 10 μL reaction mixture containing 1X of SuperMix, a reagent of Perfecta Preamp SuperMix (Quanta), 0.2μl of 0.2X primer pool (1X = 500nM Forward and 900nM Reverse), and 5 μL of cDNA. A negative control containing all the reagents except the cDNA template was included with each set of reaction mixtures. The preamplification program involved 10 min at 95°C, followed by 14 cycles of 15 s at 95°C and 4 min at 6°C. Immediately after the pre-amplification PCR, products were diluted (1:4) and stored at -80°C prior to use in qPCR.

For the qPCR array, 48 x 6 μL reaction mixture containing 1X of RNA UltraSense^™^ master mix, 1X of ROX reference dye and 0.27 μL of RNA UltraSense^™^ enzyme mix, which are components of the RNA UltraSense^™^ One-Step Quantitative RT-PCR System (Life Technologies), 1X of 20X GE Sample Loading Reagent (Fluidigm) and 2.7 μL of DNA extract were charged on the right part of the "48.48 Dynamic Array IFC" plate (BioMark). Negative controls containing all the reagents except the DNA template were included with each set of reaction mixtures. In addition, 48 x 5 μl of a mix of 500 nM of forward primer, 900 nM of reverse primer and 250 nM of probe were deposited on the left part of the plate.

Nine nl of reaction volume mix were charged onto each of the 2304 chambers on the chip with the IFC controller MX.

The qPCR program involved a 15 min denaturation step at 95°C followed by 45 cycles of 15 s at 95°C, 1 min at 60°C and 1 min at 65°C. Fluorescence was recorded by the apparatus at the end of the elongation steps (1 minute at 65°C) for each amplification cycle. Negative samples gave no Ct value.

Results {#sec011}
=======

Conventional RT-qPCR and nanofluidic PCR (RT-dPCR, RT-qPCR array) {#sec012}
-----------------------------------------------------------------

The sensitivity of conventional qPCR assays targeting 21 viral genomes was compared to the quantitative digital RT-PCR array and to the qualitative nanofluidic real-time PCR array performed on Fluidigm's BioMark System.

Quantitative detection by conventional and digital real time RT-PCR assays {#sec013}
--------------------------------------------------------------------------

Digital RT-PCR's potential for sensitive and accurate quantification was assessed on 10-fold dilution series of 21 viral genomes ([Table 3](#pone.0147832.t003){ref-type="table"}). The sensitivity was slightly better with RT-qPCR than with RT-dPCR for ten viruses by a factor ranging from 0.3 to 0.9 log~10~ and for four viruses by a factor ranging from 1.3 to 1.6 log~10~. Conversely, sensitivity was better with RT-dPCR than with RT-qPCR for seven viruses by a factor ranging from 0.1 to 1.4 log~10~.

10.1371/journal.pone.0147832.t003

###### Comparison of RT-qPCR, RT-dPCR and RT-PCR array assays.

Characteristics of standard curves based on the RT-qPCR assays and limit of detection (LOD) of viral targets by RT-qPCR, by RT-dPCR and RT-PCR array assays. The differences between relative quantification (by RT-qPCR) and absolute quantification (by RT-dPCR) were indicated.

![](pone.0147832.t003){#pone.0147832.t003g}

  Virus               Sample    RT-qPCR (CFX96)   RT-dPCR (FLUIDIGM)          RT-PCR Array (FLUIDIGM)                                                                   
  ------------------- --------- ----------------- -------------------- ------ ------------------------- -------------- ---------- ---------- ------- ------- ---------- -------
  Bocavirus           DNA ss    Plasmidic DNA     -3.20 ± 0.20         106%   0.966                     16.90--37.36   0.20       0.80       -0.60   0.17    1.00       -0.70
  Parvovirus B19      DNA ss    Plasmidic DNA     -3.05 ± 0.14         113%   0.980                     15.22--36.35   0.10       4.00       -1.60   -0.31   1.00       -1.00
  Sapovirus           RNA+ ss   Transcript RNA    -3.55 ± 0.29         91%    0.963                     20.21--36.01   1.00E+01   4.00E+01   -0.60   0.89    1.00E+02   -1.00
  Hepatitis E virus   RNA+ ss   Transcript RNA    -3.49 ± 0.23         93%    0.972                     19.91--38.15   1.00E+01   4.00E+01   -0.60   1.25    1.00E+02   -1.00
  TBEV                RNA+ ss   Transcript RNA    -3.10 ± 0.21         110%   0.970                     21.66--37.54   1.00E+01   7.90E+01   -0.90   1.03    1.00E+04   -3.00
  Aichi virus         RNA+ ss   Transcript RNA    -3.34 ± 0.46         99%    0.933                     27.18--36.53   1.00E+03   7.89E+02   0.10    1.32    1.00E+05   -2.00
  229E                RNA+ ss   Transcript RNA    -3.05 ± 0.37         113%   0.934                     25.97--36.89   2.00E+01   3.95E+02   -1.30   1.64    1.00E+03   -1.70
  HKU1                RNA+ ss   Transcript RNA    -3.41 ± 0.22         97%    0.982                     25.84--36.34   2.00E+01   7.90E+01   -0.60   1.57    1.00E+04   -2.70
  Cosavirus           RNA+ ss   Transcript RNA    -3.16 ± 0.27         107%   0.978                     24.26--31.41   1.00E+03   7.90E+01   1.10    1.35    1.00E+04   -1.00
  Norovirus GGI       RNA+ ss   Transcript RNA    -3.37 ± 0.28         98%    0.973                     26.97--38.43   1.00E+02   7.90E+01   0.10    1.44    1.00E+03   -1.00
  Norovirus GGIV      RNA+ ss   Transcript RNA    -3.53 ± 0.35         92%    0.952                     22.7--37.92    2.00E+03   7.90E+01   1.40    1.51    1.00E+03   0.30
  Norovirus GGII      RNA+ ss   Transcript RNA    -3.44 ± 0.32         95%    0.954                     23.01--38.53   1.00E+02   7.90E+01   0.10    1.64    1.00E+03   -1.00
  OC43                RNA+ ss   Transcript RNA    -3.39 ± 0.31         97%    0.952                     22.84--37.70   1.00E+01   3.95E+02   -1.60   1.67    1.00E+04   -3.00
  NL63                RNA+ ss   Transcript RNA    -3.31 ± 0.83         100%   0.851                     28.59--36.63   2.00E+02   3.95E+02   -0.30   1.97    1.00E+04   -1.70
  Hepatitis A virus   RNA+ ss   Transcript RNA    -3.27 ± 0.46         102%   0.916                     26.03--39.80   1.00E+02   3.95E+02   -0.60   2.14    1.00E+03   -1.00
  Adenovirus 41       DNA ds    Stool             -3.00 ± 0.16         115%   0.986                     23.43--35.08   1.00E+02   7.90E+01   0.10    1.47    1.00E+02   0.00
  Astrovirus          RNA+ ss   Stool             -3.65 ± 0.54         88%    0.943                     32.88--42.23   2.00E+02   7.89E+03   -1.60   3.40    1.00E+05   -2.70
  Rotavirus Wa        RNA+ ds   Cell production   -3.51 ± 0.79         93%    0.812                     22.05--36.45   1.00E+02   7.89E+02   -0.90   1.56    1.00E+04   -2.00
  MNV-1               RNA+ ss   Cell production   -3.01 ± 0.32         115%   0.947                     28.33--38.14   1.00E+02   3.95E+02   -0.60   1.95    1.00E+04   -2.00
  Enterovirus         RNA+ ss   Cell production   -3.36 ± 0.59         98%    0.894                     25.28--36.79   1.00E+03   3.95E+02   0.40    1.97    1.00E+03   0.00
  Mengovirus          RNA+ ss   Cell production   -3.21 ± 0.20         105%   0.983                     26.77--38.00   1.00E+02   7.89E+02   -0.90   2.05    1.00E+04   -2.00

^a^ LOD expressed as number of genome copies/μl of nucleic acids.

^b^ formula = \[log~10~(OD)-log~10~(digital)\].

The expected numbers of genome copies calculated *via* the standard curve by RT-qPCR were close to the direct measurement of the target concentrations by RT-dPCR only by testing DNA from plasmids. By testing RNA transcripts, the numbers of genome copies as determined by direct RT-dPCR measurement of the target concentrations were 0.9 to 2.1 log~10~ lower than the expected copy numbers calculated *via* the standard curve by RT-qPCR. Similarly, by testing genomes from viruses in stools and RNA from virus production in cells, the limit of detection (LOD) as determined by RT-dPCR was respectively 1.5 to 3.4 log~10~ and 1.6 to 2.1 log~10~ lower than the expected copy numbers calculated *via* the standard curve by RT-qPCR.

Sensitive and accurate detection by RT-qPCR array {#sec014}
-------------------------------------------------

The potential of the RT-PCR array for sensitive detection was assessed on a dilution series of 21 viral genomes ([Table 3](#pone.0147832.t003){ref-type="table"}). The limits of detection obtained with RT-qPCR array assays ranged from 1 to 10^3^ genome copies / μl of RNA / DNA extracts for 11 viruses and from 10^4^ to 10^5^ genome copies / μl of RNA extracts for the others. RT-qPCR array assays commonly showed a slightly lower sensitivity than conventional RT-qPCR. The sensitivity of both RT-qPCR and RT-qPCR array assays was found to be similar for two viruses (enterovirus, adenovirus 41), and was slightly better with the RT-qPCR than with the RT-qPCR array for 18 viruses by a factor ranging from 0.7 to 3.0 log~10~. Conversely, sensitivity was only 0.3 log~10~ higher with the RT-qPCR array than with conventional RT-qPCR assays for norovirus GIV detection.

Viral screening by RT-qPCR array and quantitative detection of clinical samples by RT-dPCR {#sec015}
------------------------------------------------------------------------------------------

The nanofluid-based (RT)-PCR assays developed were applied to characterize 25 samples (4 culture supernatants and 21 clinical samples previously characterized by NRC) for detection of hepatitis (HAV, HEV) and enteric virus genomes. First, the samples were tested on the RT-PCR array to perform a qualitative screening of the 19 viral genomes. Then the viral-positive samples were specifically quantified by RT-dPCR and by conventional RT-qPCR. Results are shown on [Table 4](#pone.0147832.t004){ref-type="table"}.

10.1371/journal.pone.0147832.t004

###### Screening and viral quantification in clinical samples (stools and viral supernatants from cell culture) by RT-qPCR and novel nanofuidic approaches (RT-qPCR and RT-dPCR).

Samples were firstly screened by RT-PCR array and then quantified by RT-dPCR. Absolute viral quantification (by RT-dPCR) was compared to relative quantification (by RT-qPCR).

![](pone.0147832.t004){#pone.0147832.t004g}

  Sample number   Nature            Origine                      NRC Virus identification   PCR Array 48x48 detection   RT-dPCR quantification [^a^](#t004fn001){ref-type="table-fn"}   RT-qPCR quantification [^a^](#t004fn001){ref-type="table-fn"}   Difference between quantification type
  --------------- ----------------- ---------------------------- -------------------------- --------------------------- --------------------------------------------------------------- --------------------------------------------------------------- ----------------------------------------
  HM175/18f       Cell production   ATCC                         HAV                        3/3                         1.51E+09                                                        4.50E+10                                                        1.47
  EchoV           Cell production   Echovirus 19. Burke strain   EV                         2/2                         1.61E+09                                                        1.75E+10                                                        1.04
  Adenovirus 40   Cell production   ATCC VR-931                  Adenovirus                 2/2                         7.11E+08                                                        1.42E+10                                                        1.30
  Astrovirus GI   Cell production   N/A                          Astrovirus                 2/2                         1.76E+10                                                        2.43E+10                                                        0.14
  780627147       stool             HAV/HEV NRC                  HAV IA                     3/3                         1.29E+06                                                        2.30E+06                                                        0.25
  1181216151      stool             HAV/HEV NRC                  HAV IA                     3/3                         2.45E+09                                                        7.75E+10                                                        1.50
  1280210015      stool             HAV/HEV NRC                  HAV IB                     3/3                         7.52E+07                                                        1.50E+09                                                        1.30
  1280514230      stool             HAV/HEV NRC                  HAV IB                     3/3 (HAV)                   2.88E+08                                                        6.85E+09                                                        1.38
                                                                                            2/2 (Aichi virus)           9.17E+07                                                        2.77E+09                                                        1.48
  1280511146      stool             HAV/HEV NRC                  HEV 3c                     2/2                         7.36E+07                                                        1.41E+09                                                        1.28
  1280418084      stool             HAV/HEV NRC                  HEV 3f                     2/2                         1.43E+08                                                        1.95E+09                                                        1.13
  1280530128      stool             HAV/HEV NRC                  HEV 3f                     2/2                         1.32E+07                                                        5.21E+08                                                        1.60
  1280615097      stool             HAV/HEV NRC                  HEV 4                      2/2                         4.44E+07                                                        2.40E+08                                                        0.73
  1280522166      stool             HAV/HEV NRC                  HEV 3                      2/2                         2.60E+07                                                        5.34E+09                                                        2.31
  E7622           stool             Enteric viruses NRC          RV G12P8                   2/2                         4.84E+09                                                        7.28E+11                                                        2.18
  E8097           stool             Enteric viruses NRC          RV G1P8                    2/2                         7.83E+08                                                        4.31E+12                                                        3.74
                                                                                            1/2 (Aichi virus)           7.83E+05                                                        6.00E+07                                                        1.88
  E6841           stool             Enteric viruses NRC          Aichi virus                2/2 (Adenovirus)            4.69E+09                                                        5.85E+10                                                        1.10
                                                                                            2/2 (Astrovirus)            4.42E+08                                                        1.65E+11                                                        2.57
  E5486           stool             Enteric viruses NRC          NoV GI.4                   3/3                         1.98E+07                                                        7.79E+07                                                        0.59
  E5569           stool             Enteric viruses NRC          NoV GI.1                   3/3                         9.58E+06                                                        9.91E+07                                                        1.01
  E8050           stool             Enteric viruses NRC          NoV GI.3                   3/3                         3.96E+07                                                        7.40E+08                                                        1.27
  E6929           stool             Enteric viruses NRC          NoV GII.4                  3/3                         5.53E+07                                                        7.00E+08                                                        1.10
  E6618           stool             Enteric viruses NRC          NoV GII.7                  3/3                         8.29E+05                                                        8.03E+06                                                        0.99
  E7859           stool             Enteric viruses NRC          NoV GII.6                  3/3                         6.94E+07                                                        5.24E+08                                                        0.88
  E7022           stool             Enteric viruses NRC          NoV GII.3                  3/3                         1.95E+07                                                        2.91E+08                                                        1.17
  E6992           stool             Enteric viruses NRC          NoV GII.1                  3/3                         1.75E+06                                                        1.52E+07                                                        0.94
  \-              stool             Enteric viruses NRC          NoV GII.13                 3/3 (NoV GII)               2.95E+06                                                        1.16E+06                                                        -0.41
                                                                 \+ NoV GIV                 2/2 (NoV GIV)               3.04E+05                                                        1.84E+07                                                        1.78

^a^ expressed as number of genome copies/g (stools) or genome copies/mL (cell production).

RT-qPCR array assays detected the previously determined viruses in 100% of the samples. Furthermore, positivity for more than one virus was found in two clinical samples. A stool previously identified as positive for HAV IB was found positive for HAV and Aichi virus and a stool identified as positive for Aichi virus was found positive for Aichi virus, adenovirus and astrovirus. The stool previously identified as co-infected by NoV GII.13 and NoV GIV was confirmed positive for both viruses.

Following the viral screening of 25 samples, the 29 detected viral genomes were successfully quantified by both RT-qPCR and RT-dPCR. The number of genome copies determined for 28 viruses was lower by RT-dPCR with a difference of quantification comprised between 0 and 1 log~10~ for 7 out of the 29 samples (24%), between 1 and 2 log~10~ for 17 out of the 29 samples (59%) and higher than 2 log~10~ for 4 out of the 29 samples (14%). So the numbers of genome copies calculated by absolute quantification (RT-dPCR) were lower than the expected numbers of genome copies calculated by using standard curve of RT-qPCR except in the sample co-infected with NoV GII and NoV GIV. In the latter sample, the NoV GII quantification was 0.4 log~10~ higher by RT-dPCR than by the RT-qPCR assays (1 out of the 29 samples, *i*.*e*. 3%).

Discussion {#sec016}
==========

Enteric viruses are able to persist for long periods in the environment and can be transmitted with a low infectious dose by human contact, water, food and fomites \[[@pone.0147832.ref026]\]. They pose a significant public health concern. They are associated with gastroenteritis in humans, but also with hepatitis and other diseases including respiratory infections, conjunctivitis, aseptic meningitis, encephalitis, myocarditis, and paralysis which have high mortality rates, particularly in immunocompromised individuals \[[@pone.0147832.ref027]\]. Commonly studied groups of enteric viruses include noroviruses and hepatitis viruses, but new tools for detecting the full range of pathogenic viruses are needed for their surveillance in the environment, food samples and for outbreak investigations \[[@pone.0147832.ref028]\].

Microfluidic digital PCR (RT-dPCR) is an accurate endpoint-sensitive absolute quantification approach that makes it possible to determine the number of target copies without a standard curve. Digital PCR ((RT)-dPCR) was compared to real-time (RT)-PCR for quantifying 19 human enteric viruses and two control process viruses. For detecting viral RNA and cDNA, RT-dPCR assays were often found to be comparable in terms of sensitivity to RT-qPCR.

The number of RNA genome copies determined by digital RT-PCR was often lower than the number of copies expected using spectrophotometry. One potential cause of discrepancy between relative and absolute quantification could be errors introduced by spectrophotometric determination of the nucleic acid concentration, leading to an overestimation of the copy genome number \[[@pone.0147832.ref029], [@pone.0147832.ref030]\]. This could explain why samples from viral stocks and stools potentially containing cellular genomes (non-target RNA) and degraded (non-amplified) targets were particularly affected by quantification discrepancies. Both quantification methods were close when DNA targets were tested. One other potential cause of discrepancy might be the RT step, which is not 100% effective, so that all the RNA may not be transcribed into cDNA and therefore is not quantified by the digital PCR.

Digital RT-PCR may provide more accurate measurements than RT-qPCR, as it is not dependent on amplification efficiency. Moreover, the advantage of this novel technology is that it is more tolerant to inhibitory substances and may reduce the difficulty of quantifying viruses when inhibitors linked to the matrix-type components analysed in food or environmental virology are present \[[@pone.0147832.ref031], [@pone.0147832.ref032], [@pone.0147832.ref033]\].

Recent innovations in PCR miniaturization made it possible to conduct high-throughput qPCR in which the reactional volumes are reduced to a nanolitre, leading to a decrease in the cost per assay per sample. Recently, a microfluidic quantitative PCR (MFQPCR) system was developed to simultaneously quantify 11 major human viral pathogens and two process controls (murine norovirus, mengovirus). This system included a specific target amplification (STA) reaction to increase the amount of target genes prior to MFQPCR \[[@pone.0147832.ref034]\]. In this study, the RT-qPCR array assays were developed and enabled simultaneous detection of 48 samples with 22 targeted virus assays. The preamplification step was also necessary because low amounts of target molecules had to be detected in very small volumes of reaction (9nl). Thus, RT-qPCR array assays involve three separate steps (RT, preamplification and PCR).

Nineteen enteric viruses and two control process viruses (MNV and mengovirus) were targeted. The sensitivity of the RT-qPCR array assays was lower (by 0.8 to 3.8 log~10~) than the limits of detection obtained with conventional RT-qPCR and RT-dPCR. However, all the clinical samples tested with the RT-qPCR array assays were identified and matched the NRC results. Moreover, two stools contained more than one viral genome, and these results completed the NRC analysis. This assay is therefore useful for rapid sample screening.

In conclusion, a combination of RT-qPCR array and RT-dPCR assays could be applied to screen contaminated samples and quantify pathogenic viruses in case of outbreaks investigation and surveillance. The choice of techniques should take into account the aim of analysis, the number of targets involved and the analytical costs. To date, the RT-qPCR array includes enteric viruses frequently reported as the causes of foodborne outbreaks and some additional viruses of lesser epidemiologic importance. In future, this technology could be updated by extending the range of viral targets to gain information during epidemiological studies. For this purpose, BioMark real-time PCR system (Fluidigm) can be also used for high-throughput microfluidic real-time PCR amplification with 96.96 dynamic arrays (Fluidigm) leading to an increase of detected targets. Concerning RT-dPCR assays, it could be helpful for standardizing the quantification of enteric viruses in samples and might be extended to the quantification of other human microbiological pathogens in foods.
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